Xeris Pharmaceuticals, Inc. announced that Mr. Paul R. Edick has been appointed President and Chief Executive Officer and a member of the Board of Directors, effective January 9, 2017. Mr. Edick is a highly accomplished pharmaceutical industry executive who most recently served as CEO of Durata Therapeutics, which he and his team built, took public, and sold to Actavis PLC, now known as Allergan PLC. He succeeds Mr. Douglas Baum, who is stepping down from his role as President and Chief Executive Officer and will serve as a consultant to the company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.57 USD | +3.63% | +18.98% | +9.36% |
07-08 | Xeris Biopharma Appoints John Shannon as CEO | MT |
07-08 | Xeris Biopharma Holdings, Inc. Announces CEO Changes | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.36% | 368M | |
+61.53% | 856B | |
+38.95% | 631B | |
-3.66% | 359B | |
+15.06% | 325B | |
+9.18% | 297B | |
+5.89% | 234B | |
+16.53% | 226B | |
+15.67% | 177B | |
+2.47% | 165B |
- Stock Market
- Equities
- XERS Stock
- News Xeris Biopharma Holdings, Inc.
- Xeris Pharmaceuticals, Inc. Announces Executive Changes